(QTRX) Quanterix - Ratings and Ratios
Digital Immunoassay Platform, Multiplex Analyzer, Assay Kits, Contract Research
QTRX EPS (Earnings per Share)
QTRX Revenue
Description: QTRX Quanterix October 28, 2025
Quanterix Corporation (NASDAQ: QTRX) is a U.S.–based life-sciences firm that designs, manufactures, and markets digital immunoassay platforms aimed at advancing precision health across research and diagnostic markets in North America, Europe, the Middle East, Africa, and the Asia-Pacific.
The company’s product suite centers on its Simoa (Single Molecule Array) technology, including the HD-X instrument for ultra-sensitive protein detection, the SR-X platform that extends Simoa to a broader set of applications, and the SP-X system that enables multiplex chemiluminescent immunoassays on a planar array. Complementary consumables-beads, capture/detector reagents, enzymes, substrates-and a full line of replacement parts and antibodies are sold alongside contract-research services such as sample testing, custom assay development, and LDT (Laboratory-Developed Test) support.
Quanterix focuses on high-growth therapeutic areas-neurology, oncology, immunology, and inflammation-and serves academic and governmental labs, pharmaceutical and biotechnology firms, and contract-research organizations through direct field sales, support teams, and a network of distributors and agents.
The firm was incorporated in 2007 (formerly Digital Genomics, Inc.) and is headquartered in Billerica, Massachusetts. As of the latest filing, QTRX’s market capitalization is roughly $2.5 billion, FY 2023 revenue reached about $140 million (≈ 30 % YoY growth), and its Simoa platform is estimated to command ~15 % of the ultra-sensitive assay market-a segment benefitting from the 8 % annual rise in global biotech R&D spending.
For a data-driven valuation framework, the ValueRay analysis of QTRX provides the metrics you need to gauge upside potential.
QTRX Stock Overview
| Market Cap in USD | 248m |
| Sub-Industry | Life Sciences Tools & Services |
| IPO / Inception | 2017-12-07 |
QTRX Stock Ratings
| Growth Rating | -76.8% |
| Fundamental | 28.3% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -70.1% |
| Analyst Rating | 3.75 of 5 |
QTRX Dividends
Currently no dividends paidQTRX Growth Ratios
| Growth Correlation 3m | 71.3% |
| Growth Correlation 12m | -79.7% |
| Growth Correlation 5y | -81.3% |
| CAGR 5y | -18.37% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.22 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.46 |
| Sharpe Ratio 12m | -1.21 |
| Alpha | -82.77 |
| Beta | 1.073 |
| Volatility | 68.48% |
| Current Volume | 321.7k |
| Average Volume 20d | 496.2k |
| Stop Loss | 4.8 (-7.2%) |
| Signal | -0.13 |
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income (-70.5m TTM) > 0 and > 6% of Revenue (6% = 7.52m TTM) |
| FCFTA -0.09 (>2.0%) and ΔFCFTA 1.03pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 218.5% (prev 254.7%; Δ -36.28pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.08 (>3.0%) and CFO -29.6m > Net Income -70.5m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 6.68 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (38.9m) change vs 12m ago 1.45% (target <= -2.0% for YES) |
| Gross Margin 55.54% (prev 56.07%; Δ -0.53pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 31.87% (prev 31.32%; Δ 0.54pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -2.81 (EBITDA TTM -84.6m / Interest Expense TTM 19.3m) >= 6 (WARN >= 3) |
Altman Z'' -7.24
| (A) 0.73 = (Total Current Assets 322.1m - Total Current Liabilities 48.2m) / Total Assets 375.6m |
| (B) -1.39 = Retained Earnings (Balance) -520.6m / Total Assets 375.6m |
| warn (B) unusual magnitude: -1.39 — check mapping/units |
| (C) -0.14 = EBIT TTM -54.1m / Avg Total Assets 393.4m |
| (D) -6.27 = Book Value of Equity -521.5m / Total Liabilities 83.2m |
| Total Rating: -7.24 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 28.32
| 1. Piotroski 0.0pt = -5.0 |
| 2. FCF Yield data missing |
| 3. FCF Margin -26.23% = -7.50 |
| 4. Debt/Equity 0.12 = 2.49 |
| 5. Debt/Ebitda 1.15 = 1.55 |
| 6. ROIC - WACC (= -29.97)% = -12.50 |
| 7. RoE -22.07% = -2.50 |
| 8. Rev. Trend 33.56% = 2.52 |
| 9. EPS Trend -14.66% = -0.73 |
What is the price of QTRX shares?
Over the past week, the price has changed by +0.00%, over one month by -12.07%, over three months by -13.26% and over the past year by -64.39%.
Is Quanterix a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of QTRX is around 3.47 USD . This means that QTRX is currently overvalued and has a potential downside of -32.88%.
Is QTRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 2
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the QTRX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6 | 16.1% |
| Analysts Target Price | 6 | 16.1% |
| ValueRay Target Price | 4 | -22.2% |
QTRX Fundamental Data Overview November 04, 2025
P/S = 1.9727
P/B = 0.8977
Beta = 1.073
Revenue TTM = 125.4m USD
EBIT TTM = -54.1m USD
EBITDA TTM = -84.6m USD
Long Term Debt = 35.5m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 5.15m USD (from shortTermDebt, last quarter)
Debt = 35.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -97.4m USD (from netDebt column, last quarter)
Enterprise Value = 22.5m USD (248.1m + Debt 35.5m - CCE 261.2m)
Interest Coverage Ratio = -2.81 (Ebit TTM -54.1m / Interest Expense TTM 19.3m)
FCF Yield = -146.2% (FCF TTM -32.9m / Enterprise Value 22.5m)
FCF Margin = -26.23% (FCF TTM -32.9m / Revenue TTM 125.4m)
Net Margin = -56.23% (Net Income TTM -70.5m / Revenue TTM 125.4m)
Gross Margin = 55.54% ((Revenue TTM 125.4m - Cost of Revenue TTM 55.7m) / Revenue TTM)
Gross Margin QoQ = 46.17% (prev 54.12%)
Tobins Q-Ratio = 0.06 (Enterprise Value 22.5m / Total Assets 375.6m)
Interest Expense / Debt = 34.87% (Interest Expense 12.4m / Debt 35.5m)
Taxrate = 0.24% (-73.0k / -30.1m)
NOPAT = -54.0m (EBIT -54.1m * (1 - 0.24%)) [loss with tax shield]
Current Ratio = 6.68 (Total Current Assets 322.1m / Total Current Liabilities 48.2m)
Debt / Equity = 0.12 (Debt 35.5m / totalStockholderEquity, last quarter 292.5m)
Debt / EBITDA = 1.15 (negative EBITDA) (Net Debt -97.4m / EBITDA -84.6m)
Debt / FCF = 2.96 (negative FCF - burning cash) (Net Debt -97.4m / FCF TTM -32.9m)
Total Stockholder Equity = 319.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -18.77% (Net Income -70.5m / Total Assets 375.6m)
RoE = -22.07% (Net Income TTM -70.5m / Total Stockholder Equity 319.4m)
RoCE = -15.24% (EBIT -54.1m / Capital Employed (Equity 319.4m + L.T.Debt 35.5m))
RoIC = -16.89% (negative operating profit) (NOPAT -54.0m / Invested Capital 319.4m)
WACC = 13.08% (E(248.1m)/V(283.7m) * Re(9.97%) + D(35.5m)/V(283.7m) * Rd(34.87%) * (1-Tc(0.00)))
Discount Rate = 9.97% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 1.31%
Fair Price DCF = unknown (Cash Flow -32.9m)
EPS Correlation: -14.66 | EPS CAGR: 43.35% | SUE: 3.18 | # QB: 1
Revenue Correlation: 33.56 | Revenue CAGR: -2.67% | SUE: -3.48 | # QB: 0
Additional Sources for QTRX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle